• Hansa Biopharma posted Q1 net loss of SEK 196.3 million, widening from SEK 38.8 million a year earlier.
• Revenue fell 47.8% to SEK 34.6 million.
• Operating loss widened to SEK 142.5 million from SEK 93.4 million.
• IDEFIRIX product sales dropped to SEK 33.9 million from SEK 65.7 million.
• FDA accepted imlifidase BLA for review with a PDUFA action date set for Dec. 19, 2026, as Hansa secured a USD 30 million convertible note financing that lifted cash and cash equivalents to SEK 676.5 million.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Hansa Biopharma AB published the original content used to generate this news brief via Cision (Ref. ID: 20260423:BIT:2823:0) on April 23, 2026, and is solely responsible for the information contained therein.